Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 26, 2026

Private credit’s great divide: Imminent crisis or ‘no big deal’

View original at finance.yahoo.com
Private credit’s great divide: Imminent crisis or ‘no big deal’ (Bloomberg) -- Even in the world of private credit, which for months has pitted skeptics against true believers after some high-profile blowups, the difference of opinion has reached new heights in the past week…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • It wasn't a matter of if software problems would emerge, it was just a matter of when. The markets have just woken up

    80% confidence
  • Some software firms may benefit from AI rather than be replaced by it

    80% confidence
  • Private credit could face default rate as high as 15% due to rapid, severe AI disruption in worst-case scenario

    80% confidence
  • Blue Owl is a buy rating amid misinformation around the money manager

    80% confidence
  • The wheels are coming off the car in private credit industry

    80% confidence
  • We're not seeing bad underwriting. It's stable, rational, and performance for the top 10 players continues to be quite good

    80% confidence
  • Private credit is now big enough that it deserves this attention and focus, and it is healthy. Every single industry goes through this cycle

    80% confidence
  • SLR Investment Corp. could be viewed as a safe haven among BDCs due to only 2% allocation to software

    80% confidence
  • Problems in software sector are like a train coming down the tracks that you could see from some distance

    80% confidence
  • This is not that big of a deal. It is definitely not an '08, it has got nothing to do with '08

    80% confidence
  • Financial firms are doing dumb things in risky lending

    80% confidence
  • The push for retail money in private credit rhymes with what happened before the 2008 financial crisis

    80% confidence
  • Axa's exposure to private credit was far below that of rivals

    80% confidence
  • AI is probably the most disruptive technology risk we could have imagined and it absolutely is going to disrupt a lot of software companies. But we still believe strongly that we've constructed a portfolio that will remain highly resistant to this risk

    80% confidence
  • Software companies in Blackstone's portfolio are growing faster, are larger and better capitalized and have more equity cushion beneath them

    80% confidence
  • Blue Owl's decision to halt quarterly withdrawals is a canary in the coal mine for the $1.8 trillion private credit market

    80% confidence
  • Allianz is very comfortable with its position in private credit

    80% confidence
  • Heavily indebted software firms will face refinancing challenges

    80% confidence
  • Annual recurring revenue allowed companies to trade at way too high a multiple

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com